Your browser doesn't support javascript.
Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study.
Soma, Tomomi; Fujii, Kentaro; Yoshifuji, Ayumi; Maruki, Taketomo; Itoh, Kazuto; Taniyama, Daisuke; Kikuchi, Takahide; Hasegawa, Naoki; Nakamura, Morio.
  • Soma T; Department of Nephrology, Japan Community Health care Organization Saitama Medical Center, Japan.
  • Fujii K; Department of Nephrology, Tokyo Saiseikai Central Hospital, Japan.
  • Yoshifuji A; Department of Nephrology, Tokyo Saiseikai Central Hospital, Japan.
  • Maruki T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
  • Itoh K; Department of General Internal Medicine, Tokyo Saiseikai Central Hospital, Japan.
  • Taniyama D; Department of Infectious Disease, Showa General Hospital, Japan.
  • Kikuchi T; Department of Hematology, Tokyo Saiseikai Central Hospital, Japan.
  • Hasegawa N; Department of Infectious Diseases, Keio University School of Medicine, Japan.
  • Nakamura M; Department of Pulmonary Medicine, National Hospital Organization Kanagawa Hospital, Japan.
Jpn J Infect Dis ; 75(5): 484-489, 2022 Sep 22.
Article in English | MEDLINE | ID: covidwho-2040397
ABSTRACT
Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hyperkalemia Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Jpn J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Yoken.JJID.2021.699

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hyperkalemia Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Jpn J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Yoken.JJID.2021.699